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Understanding the immunopathogenesis of chronic hepatitis B (CHB) in full will be key to delivering the hepatitis 
B virus (HBV)-cure program, allowing us to induce a range of host-leukocyte responses that act in concert to 
achieve complete viral elimination. While previous research has understandably focused on restoring the 
function of exhausted virus-specific CD8 T cells, there has been a relative lack of appreciation for the role played 
by the CD4 T cell pool and virus-specific CD4+ clones in controlling HBV infection [1]. It is well established that 
CD4 T cells exert a multitude of critical functions in host immunity, including promotion of B cell antibody 
production, driving granulocyte recruitment to sites of infection and supporting activation of antigen presenting 
cell (APC) populations via CD40:CD40L interactions [2]. Of particular relevance in the context of CHB is the ability 
of naïve CD4 T cells to differentiate into functionally distinct subsets under the control of specific transcription 
factors and polarising cytokines. Major subtypes include T-helper (Th)1 cells which produce IFNγ/IL-12, Th2 
mainly producing IL-4, Th17 producing IL-17/IL-21 (dependent upon RORγT), and the T-regulatory (T-reg) 
population which depends on FoxP3. Despite the recent focus on CD8 T cell function in HBV research, data from 



































































the 1980’s has previously indicated that CD4 T cells are the dominant supporters of CD8 T cell-mediated HBV 
responses and play essential roles in driving CD8 T cell effector function and memory formation [3]. Indeed, lack 
of CD4 T cells was even considered to be a major cause of exhaustion among virus-specific CD8 T cells, which are 
dependent upon a continued supply of multiple cytokines to maintain their effector functions [4]. In line with 
this concept, other investigators have also observed that loss of CD4 T cells during acute infection can generate a 
defective memory CD8 T cell compartment, including the loss of IL-2 production, thus mounting only weak 
responses upon secondary pathogen exposure [5]. While chronic viral infections clearly have potential to induce 
exhaustion in CD4 T cell populations similarly to their CD8 T cell counterparts, this area is notably understudied 
at present. A recent report indicated that during chronic infection, CD4 T cells display increased expression of 
mRNAs encoding transcription factors implicated in the development of different Th cell subsets. These data 
indicate that exhausted CD4 T cells do not merely diminish in their ability to produce cytokines - they also exhibit 
an altered functional profile as a consequence of change in differentiation patterns [6]. In particular, CD4 T cells 
have been shown to act as potent producers of IL-21 which likely sustains CD8 T cell responses to chronic 
infections, hence differentiation towards this functional profile may be an important determinant of patient 
outcome. In the absence of IL-21 derived from CD4 T cells, virus-specific CD8 T cells appear to lose their ability to 
produce IL-2, TNFα and IFNγ and display other hallmarks of an exhausted state (including high levels of CD43 and 
PD-1) [7]. Consistent with this finding, a recent study in CHB patients showed that combined OX40 stimulation 
and PD-L1 blockade significantly augmented IFNγ and IL-21 producing HBV-specific CD4 T cells in vitro, 
suggesting that such immunotherapeutic approaches could potentially also improve virus-specific CD4 T cells 
responses in vivo [8].  
 
Seroclearance of chronic viral infection is thought to be mediated primarily by IFNγ release, but the CD4 T cell 
pool may simultaneously exacerbate immunopathology via production of TNFα which potentially worsens 
hepatic injury (as previously described in a mouse model of concanavalin-A induced hepatitis [9]). Indeed, a 
recent study identified that IL-17 producing CD4 T cells (Th17) enriched in the blood and liver of CHB patients are 
closely associated with hepatic flares, during which they display marked expression of the pro-inflammatory 
cytokines IL-1β, IL-6, TNFα [10]. Multiple other studies also suggest that the CD4 T cell compartment may 
represent an important ‘inflammatory’ component of CHB pathology, including an increased expression of 
NKG2D ligands which blunt HBV-specific CD4 T cell responses with their interaction of the NKG2D receptor on 
NK cells [11]. Whether operating in a regulatory or pro-inflammatory role, it is clear that CD4 T cells have a 
major part to play in mediating viral clearance and control, but until recently studies in CHB have been lacking.  
 
In this edition of Journal of Hepatology, Wang et al., perform a thorough immunological analysis of the HBV-
specific CD4 T cell response in patients in various disease phases of CHB. They report that distinct subsets of 
HBV-specific CD4 T cells producing TNFα or IFNγ are associated with liver damage or viral clearance, respectively. 
The authors utilised a panel of HLA-restricted epitopes against CD4 T cells and undertook analysis with these 



































































that increasing CD4 T cell responses to HBc and HBeAg occur during seroconversion to anti-HBe and anti-HBs 
production in acute HBV infection, implying that T cells directed against these proteins are essential for viral 
elimination. In contrast, patients with CHB failed to mount an efficient T cell response to HBc/HBs, thereby 
contributing to persistence of infection [13]. Wang et al., report a significant overall expansion of TNFα-
producing, compared to IFNγ-expressing, HBc- and HBs-specific CD4 T cells in their patient cohort. Accounting 
for patient clinical parameters, the authors report a dominance of TNFα-producing HBV-specific CD4 T cells in 
HBeAg+ patients with high viral load, whereas IFNγ-expressing HBV-specific CD4 T cells instead dominated in 
patients who approached viral clearance (HBeAg seroconversion and HBsAg loss). Importantly HBsAg level 
negatively correlated with the dominance of IFNγ+ HBV-surface specific CD4 T cells. Thus viral clearance is 
accompanied by an elevation in both the frequency and dominance of antigen-specific CD4 T cells producing 
IFNγ, which has also been observed for other viral infections such as CMV [14] and bacterial infections [15]. 
 
It is now widely accepted that induction of hepatic flares in CHB may in fact aid seroclearance (HBsAg loss), such 
that discontinuation of nucleos(t)ide analogue (NA) therapy has now been described as a potential therapeutic 
strategy in a number of different studies [16]. In order to circumvent potential for excessive hepatic flares and 
possible liver failure, studies of treatment discontinuation are undertaken in a controlled manner and thus large 
flares are carefully avoided. Coinciding with this, virus-specific CD4 T cell responses in patients stopping NA 
therapy with a mild-moderate rise in transaminases demonstrate only limited virus-specific CD4 T cell responses 
[17, 18]. It is notable therefore that Wang et al., studied patients presenting with severe hepatic flares prior to 
commencing NA therapy. Consequently, they observed potent TNFα+ (core>surface) virus-specific CD4 T cell 
responses in patients with aggressive liver damage, followed by significant decreases in these responses only 
after NA introduction. In contrast, IFNγ+ virus-specific CD4 T cell responses in these patients were characteristic 
of individuals capable of clearing HBsAg [12]. These findings are consistent with previous reports of high 
circulating serum TNFα in patients with active hepatitis B [19], indicating that this cytokine may contribute to 
liver damage and immunopathology (presumably with a view to gaining viral control and allowing for 
subsequent induction of virus-specific T cells expressing IFNγ). Of note, TNFα/IFNγ double producers and IFNγ+ 
single producers were routinely detected in patients undergoing HBeAg and HBsAg seroconversion, suggesting 
that antigen specific-CD4 T cell responses transition from TNFα to IFNγ expression in individuals undergoing viral 
clearance (Figure 1). Both populations were observed to express the lineage-specific transcription factors, T-bet 
and RORγT at comparable levels, suggesting that Th1 and Th17 pathways of differentiation may be important in 
this context (although IL-21 rather than IL-17 appeared critical in this case). Further work will now be required to 
elucidate this process in full and identify the transcription factor profile associated with mono-production of 
TNFα.  
 
The importance of T cell differentiation in shaping the cytokine responses that switch patients from an 
inflammatory profile (TNFα dominated) to achieving viral clearance (IFNγ) has been underappreciated in the 



































































‘re’-opened important avenues for the future study of these crucial cells. This work should encourage other 
researchers in the field to now consider the influence of CD4 T cell differentiation pathways and downstream 
interactions with CD8 T, B and innate leukocyte populations on anti-viral responses. Such analyses should not 
only be undertaken in the blood but also within the intrahepatic compartment, both in treatment-naïve subjects 
and those undergoing therapy via longitudinal sampling [20]. Ultimately, therapeutic approaches that can 
increase T-bet expression and enhance IL-21 synthesis in patient CD4 T cells may succeed in boosting virus-







Figure 1: Diagram depicting the phenotype of an exhausted CD4 T cell in chronic hepatitis B infection. The 
expression of TNFα/IFNγ producing HBV-specific CD4 T cells during HBV infection is represented and how this 
leads to the generation of an inflammatory response or that of viral clearance respectively. A switching of 
cytokine producing from TNFα to IFNγ producing virus specific CD4 T cells may progress towards viral clearance, 
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